Evotec reported Q2/2019 revenues in line with cons. forecasts and adj. EBITDA c.8% ahead. Combined with the consolidation of Just Biotherapeutics (“Just.Bio”, closed on 2nd July), this has led management to increase financial outlook for FY2019E. Changes to our model are due largely to adding forecasts for Just.Bio and the increased debt position following the placing of a €250m Schuldschein (promissory note) in June. We maintain our OUTPERFORM recommendation and target price (“TP”) of €28 per s ....
04 Sep 2019
Biologics boost raises expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Biologics boost raises expectations
Evotec SE (EVT:WBO) | 0 0 0.7% | Mkt Cap: 2,149m
- Published:
04 Sep 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
13
Evotec reported Q2/2019 revenues in line with cons. forecasts and adj. EBITDA c.8% ahead. Combined with the consolidation of Just Biotherapeutics (“Just.Bio”, closed on 2nd July), this has led management to increase financial outlook for FY2019E. Changes to our model are due largely to adding forecasts for Just.Bio and the increased debt position following the placing of a €250m Schuldschein (promissory note) in June. We maintain our OUTPERFORM recommendation and target price (“TP”) of €28 per s ....